Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACON 
Aclarion Inc (ACON)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: ACON (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $20
1 Year Target Price $20
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.05% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.50M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 1 | Beta 1.36 | 52 Weeks Range 6.20 - 3500.41 | Updated Date 09/14/2025 |
52 Weeks Range 6.20 - 3500.41 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.12 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -8988.6% |
Management Effectiveness
Return on Assets (TTM) -44.35% | Return on Equity (TTM) -88.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4100304 | Price to Sales(TTM) 71.42 |
Enterprise Value 4100304 | Price to Sales(TTM) 71.42 | ||
Enterprise Value to Revenue 65.14 | Enterprise Value to EBITDA -0.56 | Shares Outstanding 582371 | Shares Floating 582342 |
Shares Outstanding 582371 | Shares Floating 582342 | ||
Percent Insiders - | Percent Institutions 0.77 |
Upturn AI SWOT
Aclarion Inc
Company Overview
History and Background
Aclarion, Inc. (ACLAR) is a medical device company focused on developing and commercializing novel technologies for the diagnosis of lower back pain. Founded in 2003, the company's focus has been on identifying the source of pain in the lower back to aid in the improvement of treatment outcomes.
Core Business Areas
- Nociscan Imaging System: The core business is their Nociscan imaging system, which is designed to detect biomarkers associated with painful intervertebral discs. This provides information to surgeons for deciding on whether or not to do surgery.
Leadership and Structure
Brent Stoffer is the Chief Executive Officer. The company has a typical hierarchical structure with departments for research and development, sales and marketing, and operations.
Top Products and Market Share
Key Offerings
- Nociscan Imaging System: The Nociscan Imaging System is Aclarion's main offering. It uses Magnetic Resonance Spectroscopy (MRS) to identify painful discs in the lower back. Market share data is unavailable due to the niche nature of this technology and the evolving landscape of pain management diagnostics. Competitors include traditional MRI and other diagnostic methods for back pain.
Market Dynamics
Industry Overview
The industry consists of pain management and diagnostic solutions for lower back pain. There is a trend towards more precise and objective diagnostic methods to reduce unnecessary surgeries and improve patient outcomes.
Positioning
Aclarion is positioned as an innovator in diagnostic tools for back pain. Their competitive advantage lies in using MRS technology for direct identification of painful discs, which is a novel approach.
Total Addressable Market (TAM)
The TAM for lower back pain diagnostics is substantial, estimated to be in the billions of dollars globally. Aclarion is positioned to capture a portion of this market by providing a more precise diagnostic tool than standard practices.
Upturn SWOT Analysis
Strengths
- Novel technology
- Potential for improved diagnostic accuracy
- Focus on unmet medical needs
Weaknesses
- Limited commercial traction
- High development costs
- Requires specialized equipment and training
Opportunities
- Expansion into new markets
- Partnerships with hospitals and clinics
- Further development of diagnostic applications
Threats
- Competition from established diagnostic methods
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- GE (GE)
- SIEMENS (SIE.DE)
- PHILIPS (PHG)
Competitive Landscape
Aclarion faces intense competition from established players in the medical imaging industry, which have significant resources. Its main advantage is its novel technology.
Growth Trajectory and Initiatives
Historical Growth: Historical Growth is unavailable.
Future Projections: Future projections are unavailable. Future growth depends on regulatory approvals, market adoption, and financing.
Recent Initiatives: Recent initiatives include clinical studies to validate the efficacy of the Nociscan system and secure regulatory approvals.
Summary
Aclarion Inc. is a company with potential due to its novel technology in diagnosing lower back pain. However, it faces challenges in commercializing its product and competing with larger, established players. Future success hinges on regulatory approvals and market adoption. The company needs to obtain strategic funding to propel sales. The stock currently seems weak.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Third party market data sources
Disclaimers:
This analysis is based on publicly available information and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aclarion Inc
Exchange NASDAQ | Headquaters Broomfield, CO, United States | ||
IPO Launch date 2022-04-22 | CEO, President & Director Mr. Brent Ness | ||
Sector Healthcare | Industry Health Information Services | Full time employees 5 | Website https://www.aclarion.com |
Full time employees 5 | Website https://www.aclarion.com | ||
Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.